Antiviral therapies and prospects for a cure of chronic hepatitis B

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 4, 2015, Pages

  Zoulim, Fabien ^a   Durantel, David ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; ALPHA INTERFERON; ENTECAVIR; GUANINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CLINICAL FEATURE; CROSS RESISTANCE; DECOMPENSATED LIVER CIRRHOSIS; DRUG TREATMENT FAILURE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; NONHUMAN; PREDICTION; SEROCONVERSION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS NUCLEOCAPSID; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; COMBINATION DRUG THERAPY; DISEASE MANAGEMENT; DISEASE MODEL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; MOUSE; PATHOGENICITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

HEPATITIS B VIRUS;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MANAGEMENT; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TENOFOVIR; TREATMENT OUTCOME;

EID: 84923769732     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021501     Document Type: Article

References (115)

1. Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N. 2006. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443: 590– 593.
2. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, Raimondo G, Levrero M. 2009. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci 106: 19975–19979.
3. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. 2012. IFN-a inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122: 529–537.
4. Belloni L, Li LC, Palumbo GA, Chirapu SR, Calvo L, Finn M, Lopatin U, Zlotnick A, Levrero M. 2013. HAPs hepatitis B virus (HBV) capsid inhibitors block core protein inter-action with the viral minichromosome and host cell genes and affect cccDNA transcription and stability. Hepatology 58: 277.
5. Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty JF Jr, McHutchison JG, et al. 2014. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in ade-fovir-experienced chronic hepatitis B patients. J Hepatol 60: 715–722.
6. Bertoletti A, Ferrari C. 2012. Innate and adaptive immune responses in chronic hepatitis B virus infections: Towards restoration of immune control of viral infection. Gut 61: 1754–1764.
7. Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F. 2011. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res 92: 271–276.
8. Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B, Ebling M, Korba B, Lansky DM, Jacob GS, Dwek RA. 1998. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 4: 610–614.
9. Bojang P Jr, Ramos KS. 2014. The promise and failures of epigenetic therapies for cancer treatment. Cancer Treat Rev 40: 153–169.
10. Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, et al. 2012. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide ana-logues. Gastroenterology 143: 963–973.e9.
11. Buti M. 2014. HBeAg-positive chronic hepatitis B: Why do I treat my patients with nucleos(t)ide analogs? Liver Int 34: 108–111.
12. Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo JT, Block TM, et al. 2012. Identification of the disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 56: 4277– 4288.
13. Xu X, Guo JT, Block TM, et al. 2012. Identification of the disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 56: 4277– 4288.
14. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, Pichoud C, Naesens L, Neyts J, Trepo C, Zoulim F. 2008. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naïve patients is not due to pre-existing drug-resistant mutants. Antivir Ther 13: 381–388.
15. Chan HL, Chan CK, Hui AJ, Chan S, Poordad F, Chang TT, Mathurin P, Flaherty JF, Lin L, Corsa A, et al. 2014. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine amino-transferase and high levels of hepatitis B virus DNA. Gastroenterology 146: 1240–1248.
16. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J. et al. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010.
17. YC, Lok AS, Han KH, Goodman Z, Zhu J. et al. 2006. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010.
18. Cho J-Y, Paik Y-H, Sohn W, Cho HC, Gwak G-Y, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. 2014. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut 63: 1943–1950.
19. Delaney WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. 2002. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 46: 3057–3060.
20. Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J, et al. 2003. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299: 893–896.
21. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. 2003. Histological outcome during long-term lamivudine ther-apy. Gastroenterology 124: 105–117.
22. Dupinay T, Gheit T, Roques P, Cova L, Chevallier-Queyron P, Tasahsu SI, Le Grand R, Simon F, Cordier G, Wakrim L, et al. 2013. Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fasci-cularis from Mauritius Island. Hepatology 58: 1610– 1620.
23. Durantel D, Zoulim F. 2012. Interplay between hepatitis B virus and TLR2-mediated innate immune responses: Can restoration of TLR2 functions be a new therapeutic op-tion? J Hepatol 57: 486–489.
24. Durantel D, Brunelle M-N, Gros E, Carrouée-Durantel S, Pichoud C, Villet S, Trepo C, Zoulim F. 2005. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: From genotypic to phenotypic testing. J Clin Virol 34: S34–S43.
25. EASL. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57: 167– 185.
26. Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, Hussain M, Cursaro C, Richtmyer P, Marrero JA, et al. 2005. Adefovir-resistant hepatitis B can be asso-ciated with viral rebound and hepatic decompensation. J Hepatol 43: 937–943.
27. Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann H-W, Gurel S, Caruntu FA, Flaherty JF, Massetto B, et al. 2014. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 146: 980–988.
28. Gane EJ, Deray G, Liaw Y-F, Lim SG, Lai C-L, Rasenack J, Wang Y, Papatheodoridis G, Di Bisceglie A, Buti M, et al. 2014. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 146: 138– 146.e5.
29. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, et al. 2007. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133: 1437–1444.
30. Gish R, Jia JD, Locarnini S, Zoulim F. 2012. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 12: 341–353.
31. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, et al. 2013. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology 58: 505–513.
32. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C. 1988. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of di-methyl sulfoxide. J Virol 62: 4136–4143.
33. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. 2002. Infection of a human hepatoma cell line by hepa-titis B virus. Proc Natl Acad Sci 99: 15655–15660.
34. Gruffaz M, Testoni B, Luangsay S, Fusil F, Malika AG, Man-cip J, Petit MA, Javanbakht H, Cosset FL, Zoulim F, et al. 2013. The nuclear function of hepatitis B capsid (HBc) protein is to inhibit IFN response very early after infection of hepatocytes. Hepatology 58: 276A.
35. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, et al. 2006. Long-term therapy with adefovir dipi-voxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131: 1743–1751.
36. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, et al. 2011. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140: 132–143.
37. Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, et al. 2014. Late HDV RNA relapse after peginterferon a-based therapy of chronic hepatitis delta. Hepatology 60: 87–97.
38. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, et al. 2013. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58: 98–107.
39. Janssen HLA, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TMK, Gerken G, de Man RA, et al. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 365: 123– 129.
40. Jones PA. 2014. At the tipping point for epigenetic therapies in cancer. J Clin Invest 124: 14–16.
41. Jordheim LP, Durantel D, Zoulim F, Dumontet C. 2013. Advances in the development of nucleoside and nucleo-tide analogues for cancer and viral diseases. Nat Rev Drug Discov 12: 447–464.
42. Kao JH. 2014. HBeAg-positive chronic hepatitis B: Why do I treat my patients with pegylated interferon? Liver Int 34: 112–119.
43. Kennedy PT, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR, Bertoletti A. 2012. Preserved T-cell function in children and young adults with immune-tol-erant chronic hepatitis B. Gastroenterology 143: 637–645.
44. Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. 2014. No de-tectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 59: 434–442.
45. Knolle PA, Thimme R. 2014. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146: 1193–1207.
46. Koniger C, Wingert I, Marsmann M, Rosler C, Beck J, Nassal M. 2014. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci 111: E4244–E4253.
47. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, et al. 2013. Com-bination of DNA prime—Adenovirus boost immuniza-tion with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PloS Pathog 9: e1003391.
48. Lai CL, Yuen MF. 2013. Prevention of hepatitis B virus-re-lated hepatocellular carcinoma with antiviral therapy. Hepatology 57: 399–408.
49. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, et al. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354: 1011–1020.
50. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. 2007. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 47: 760–767.
51. Lampertico P, Liaw YF. 2012. New perspectives in the ther-apy of chronic hepatitis B. Gut 61: 18–24.
52. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, Fosdick A, Frey CR, Zheng J, Wolfgang G, et al. 2013. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144: 1508–1517.
53. Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, et al. 2005. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682–2695.
54. Lavocat F, Deny P, Pichoud C, Al Hawajri N, Kitrinos K, Borroto-Esoda K, Zoulim F. 2013. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol 59: 684–695.
55. Lazar C, Durantel D, Macovei A, Zitzmann N, Zoulim F, Dwek RA, Branza-Nichita N. 2007. Treatment of hepatitis B virus-infected cells with a-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res 76: 30–37.
56. Le Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, Li XY, Chen SH, King I, Trepo C, et al. 2000. Characterization of the antiviral effect of 20,30 -dideoxy-20,30 -didehydro-b-L-5-fluorocytidine in the duck hepa-titis B virus infection model. Antimicrob Agents Chemother 44: 111–122.
57. Le Guerhier F, Pichoud C, Jamard C, Guerret S, Chevallier M, Peyrol S, Hantz O, King I, Trepo C, Cheng YC, et al. 2001. Antiviral activity of b-L-20,30 -dideoxy-20,30 -dide-hydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob Agents Chemother 45: 1065–1077.
58. Li T, Robert EI, van Breugel PC, Strubin M, Zheng N. 2010. A promiscuous a-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery. Nat Struct Mol Biol 17: 105–111.
59. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, et al. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521–1531.
60. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, et al. 2011a. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized open-label study. Hepatology 54: 91–100.
61. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, et al. 2011b. Tenofovir disoproxil fumarate (TDF), em-tricitabine/TDF, and entecavir in patients with decom-pensated chronic hepatitis B liver disease. Hepatology 53: 62–72.
62. Liu Y, Kitrinos KM. 2013. In vitro phenotyping of recom-binant hepatitis B virus containing the polymerase/ reverse transcriptase gene from clinical isolates. Methods Mol Biol 1030: 163–181.
63. Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji D, Wang H, Xin S, Zoulim F, Xu D. 2010. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther 15: 1185–1190.
64. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, et al. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: 1714– 1722.
65. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Haber-setzer F, Sievert W, Wong D, Lovegren M, Cohen D, et al. 2012. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 143: 619– 628.e1.
66. Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, Zoulim F, Hantz O, Protzer U. 2011. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55: 996–1003.
67. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, et al. 2014. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343: 1221–1228.
68. Lutgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, et al. 2012. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55: 685–694.
69. Marcellin P, Lau GKK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu Z-M, Piratvisuth T, Germanidis G, Yurdaydin C, et al. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with hbeag-neg-ative chronic hepatitis B. N Engl J Med 351: 1206–1217.
70. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, et al. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359: 2442– 2455.
71. Mason WS, Litwin S, Jilbert AR. 2008. Immune selection during chronic hepadnavirus infection. Hepatol Int 2: 3–16.
72. Maynard M, Parvaz P, Durantel S, Chevallier M, Chevallier P, Lot M, Trepo C, Zoulim F. 2005. Sustained HBs sero-conversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. J Hepatol 42: 279–281.
73. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, et al. 2013. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-a therapy of chronic hepatitis B. J Hepatol 58: 225–233.
74. Michel ML, Deng Q, Mancini-Bourgine M. 2011. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and chal-lenges. J Hepatol 54: 1286–1296.
75. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. 1997. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 71: 9392– 9399.
76. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, et al. 2014. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146: 1070–1083.
77. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser- Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. 2014. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 60: 723–731.
78. Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, et al. 2012. Long-term continuous entecavir therapy in nucleos (t)ide-naïve chronic hepatitis B patients. J Hepatol 57: 508–514.
79. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptoppoulou-Gigi M, Vasiladis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, et al. 2011. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antivi-ral(s) starting with lamivudine monotherapy: Results of the nationwide HEPNET. Greece cohort study. Gut 60: 1109–1116.
80. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, et al. 2011. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipi-voxil in chronic hepatitis B. Gut 60: 247–254.
81. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, et al. 2008. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26: 335–341.
82. Sadler AJ, Williams BRG. 2008. Interferon-inducible antivi-ral effectors. Nat Rev Immunol 8: 559–568.
83. Samuel CE. 2001. Antiviral actions of interferons. Clin Microbiol Rev 14: 778–809.
84. Scaglione SJ, Lok AS. 2012. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 142: 1360– 1368.e1.
85. Seeger C, Zoulim F, Mason WS. 2014. Hepadnaviruses. In Field’s virology (ed. Knipe DM, Howley PM), p. 2185. Lippincott Williams & Wilkins, Philadelphia.
86. Shlomai A, Schwartz RE, Ramanan V, Bhattaa de Jongyp YP, Bhatiasn YP, Rice CM. 2014. Modeling host interactions with hepatitis B virus using primary and induced plurip-otent stem cell-derived hepatocellular systems. Proc Natl Acad Sci 111: 12193–12198.
87. Sogni P, Carrieri MP, Fontaine H, Mallet V, Vallet-Pichard A, Trabut JB, Meritet JF, Pol S. 2012. The role of adherence in virological suppression in patients receiving anti-HBV analogues. Antivir Ther 17: 395–400.
88. Sohn JA, Litwin S, Seeger C. 2009. Mechanism for CCC DNA synthesis in hepadnaviruses. PLoS ONE 4: e8093.
89. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, et al. 2014. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study. Hepatology 59: 1283–1292.
90. Thimme R, Dandri M. 2013. Dissecting the divergent effects of interferon-a on immune cells: Time to rethink com-bination therapy in chronic hepatitis B? J Hepatol 58: 205–209.
91. Urban S, Bartenschlager R, Kubitz R, Zoulim F. 2014. Strat-egies to inhibit entry of HBVand HDV into hepatocytes. Gastroenterology 147: 48–64.
92. Vigano M, Mangia G, Lampertico P. 2014. HBeAg-negative chronic hepatitis B: Why do I treat my patients with nucleos(t)ide analogues? Liver Int 34: 120–126.
93. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F. 2007. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46: 531–538.
94. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F. 2008. Impact of hepatitis B virus rtA181 V/T mutants on hepatitis B treatment failure. J Hepatol 48: 747–755.
95. Vlachogiannakos J, Papatheodoridis GV. 2014. HBeAg-neg-ative chronic hepatitis B: Why do I treat my patients with pegylated interferon-alfa? Liver Int 34: 127–132.
96. Warner N, Locarnini S. 2008. The antiviral drug selected hepatitis B virus rtA181T/sW172� mutant has a domi-nant negative secretion defect and alters the typical pro-file of viral rebound. Hepatology 48: 88–98.
97. Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Naga-mori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, et al. 2014. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 59: 1726–1737.
98. Welsch C, Jesudian A, Zeuzem S, Jacobson I. 2012. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61: i36–i46.
99. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, et al. 2004. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126: 1750–1758.
100. Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF. 2013. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide ana-logues of different potency. Clin Gastroenterol Hepatol 11: 1004–1010.
101. Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, Hegge JO, Klein JJ, Wakefield DH, Oropeza CE, et al. 2013. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 21: 973–985.
102. Wu C-Y, Lin J-T, Ho HJ, Su C-W, Lee T-Y, Wang S-Y, Wu C, Wu J-C. 2014. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B—A nationwide cohort study. Gastroenterology 147: 143–151.e5.
103. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, et al. 2012. Sodium taurocholate co-transporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1: e00049.
104. Yu W, Goddard C, Clearfield E, Mills C, Xiao T, Guo H, Morrey JD, Motter NE, Zhao K, Block TM, et al. 2011. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem 54: 5660–5670.
105. Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak JF, Roggendorf M, Lu M. 2012. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol 57: 522–528.
106. Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason WS. 2001. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 75: 311–322.
107. Zimmerman KA, Fischer KP, Joyce MA, Tyrrell DL. 2008. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol 82: 8013– 8021.
108. Zlotnick A, Mukhopadhyay S. 2011. Virus assembly, allo-stery and antivirals. Trends Microbiol 19: 14–23.
109. Zoulim F. 2011. Hepatitis: Treatment failure in chronic hepatitis B. Nat Rev Gastroenterol Hepatol 8: 366–367.
110. Zoulim F. 2012. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res 96: 256–259.
111. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593– 1608. e1591–e1592.
112. Zoulim F, Mason WS. 2012. Reasons to consider earlier treatment of chronic HBV infections. Gut 61: 333–336.
113. Zoulim F, Saputelli J, Seeger C. 1994. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 68: 2026–2030.
114. Zoulim F, Luangsay S, Durantel D. 2013a. Targeting innate immunity: A new step in the development of combination therapy for chronic hepatitis B. Gastroenterology 144: 1342–1344.
115. Zoulim F, Testoni B, Lebosse F. 2013b. Kinetics of intrahe-patic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: Lessons from experimental and clinical stud-ies. Clin Gastroenterol Hepatol 11: 1011–1013.